BACKGROUND: MYBPC3 splicing errors are a common cause of hypertrophic cardiomyopathy (HCM). Variants affecting essential splicesite dinucleotides inhibit splicing, whereas the impact of variants at conserved flanking nucleotides is less clear. We evaluated the contribution of MYBPC3 splice-site variants in a large cohort of patients with HCM and assessed the impact on splicing with RNA analysis.
H ypertrophic cardiomyopathy (HCM) is an inherited structural disease of the myocardium with a prevalence of ≤1 in 200 individuals. 1 HCM is diagnosed on finding a maximal left ventricular septal thickness ≥15 mm in adults or ≥13 mm in those with a positive family history of HCM, in the absence of another explanation for the extent of hypertrophy. 2, 3 People with HCM can range in presentation from no symptoms, or mild symptoms with a relatively benign clinical course, to severe complications, including heart failure and sudden cardiac death. HCM is generally considered to be an autosomal dominant disorder caused by heterogeneous variants in any 1 of 8 genes encoding proteins of the sarcomere. 4 The majority of pathogenic variants are nonsense and frameshift variants in MYB-PC3, and missense variants in MYH7. 5 Errors of RNA splicing are a common cause of frameshifts in MYBPC3. 5 RNA splicing is the post-transcriptional processing of primary RNA transcripts, which removes noncoding intron sequences and joins together protein-coding exon sequences to form mRNA. Conserved sequences at the beginning of introns (5′ donor splice site) and end of introns (3′ acceptor splice site) are required for intron recognition and excision ( Figure 1 ). The donor and acceptor splice sites include an almost invariant GT and AG dinucleotide at the immediate beginning and end of introns, respectively. 6, 7 Variants at the essential splice-site dinucleotides invariably cause RNA splicing errors, whereas variants at well-conserved flanking regions may also disrupt splicing; however, this requires confirmation with analysis of mRNA sequence.
Variants at the essential GT and AG splice dinucleotides of MYBPC3 are significantly enriched in familial HCM and are typically classified as pathogenic or likely pathogenic because they cause RNA splicing errors and lead to frameshifts. 5 Rare variants flanking the essential splice dinucleotides of MYBPC3 are also commonly found in familial HCM, but they often have uncertain clinical significance because their impact on splicing cannot be determined from sequence context alone. However, demonstration that such variants cause RNA splicing errors may add sufficient additional evidence for reclassification to likely pathogenic or pathogenic and provide a precise genetic cause of disease that can be used for cascade genetic testing of family members.
Here, we evaluate the contribution of MYBPC3 splice-site variants in patients with HCM and perform functional analysis of variants using RNA extracted from patient's fresh venous blood and archival fixed septal myectomy tissue. We demonstrate the key benefit of RNA studies for variant reclassification using the modified guidelines of the American College of Medical Genetic and Genomics and the Association for Molecular Pathology (ACMG/AMP).
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METHODS
Participants, or next of kin, provided informed consent for genetic testing, and all studies were performed in strict approval and in accordance with the Sydney Local Health District Ethics Review Committee, Australia. All data, analytical methods, and study materials supporting this study are available from the corresponding author on reasonable request for purposes of reproducing the results or replicating the procedures, after approval from the Sydney Local Health District Ethics Review Committee. A full description of the Methods is provided in the Data Supplement.
RESULTS
MYBPC3 Splice-Site Variants in Patients With HCM
We found 29 rare or novel MYBPC3 splice-site variants in 56 of 557 (10%) unrelated HCM probands ( Figure 2 ). Thirteen variants altered an essential AG or GT splice dinucleotide or created a nonsense variant or an insertion or deletion leading to a frameshift and were classified as pathogenic (Table I in the Data Supplement) . Three splice-site variants were not predicted to alter splicing and were classified as benign; one of which was found in a patient with a pathogenic MYBPC3 Arg502Gln variant and another in a patient with 2 variants of uncertain clinical significance; Glu441Lys in MYBPC3 and Arg278Cys in TNNT2 (Table II in the Data Supplement) . The remaining 13 splice-site variants were predicted to alter splicing and were found in 33 of 557 (6%) unrelated probands, of which only 3 probands had an additional rare variant found in 46 cardiomyopathy genes (Table 1) .
RNA Analysis of MYBPC3 Splice Region Variants
Fresh venous blood or fixed myocardial tissue was available to extract RNA from 16 people with HCM for functional analysis of 9 MYBPC3 splice-site variants ( Table 2 ). We assayed 4 donor splice-site variants predicted to disrupt splicing. A c.654+5G>C variant caused splicing to occur from a cryptic donor splice sequence within the middle of exon 5, leading to a truncated exon of 101 bp and an in-frame deletion of 48 bp ( Figure 3A and 3B) . A c.821+3G>T variant was found in a male proband (BJR1) and his affected brother (BJR4). The proband was diagnosed at 12 years of age with severe obstructive HCM, with a maximal septal wall thickness of 40 mm ( Table 2) . He underwent a septal myectomy in 2016, after which a segment of resected myocardium was formalin fixed and embedded in paraffin wax. Analysis of RNA extracted from fresh venous blood of both affected family members, and the fixed myocardial tissue of BJR1, showed skipping of exon 7 ( Figure 3C and 3D) . A c.1624+4A>T variant caused skipping of exon 17 in 2 members of family I and an unrelated proband of family CZ, leading to a frameshift, whereas a c.3190+5G>A variant amplified correctly spliced transcripts only (Figure IA and IB in the Data Supplement).
We found 3 splice acceptor variants predicted to disrupt splicing, and fresh venous blood was available to assess 2; a recurrent c.927-9G>A variant in intron 11, found in 5 families, and a c.3491-3C>G variant in intron 31 found in 1 family. We could not confirm that the c.927-9G>A variant caused splicing errors in 2 unrelated probands ( Figure IC in the Data Supplement). Five of 6 people with the c.927-9G>A variant had mild HCM, with a maximal septal wall thickness ranging from 15 to 18 mm, whereas one had a wall thickness of 24 mm, experienced palpitations, and had an implantable cardioverter defibrillator. The c.3491-3C>G variant caused skipping of exon 32, leading to a frameshift in MYBPC3 and was found in a woman with mild HCM, maximal septal wall thickness of 14 mm, and a family history of HCM (Table 2; Figure ID in the Data Supplement).
Finally, we found 6 missense variants that were predicted to disrupt splicing, and fresh venous blood was available to assess the effects of 3; c.772G>A (p.Glu258Lys), c.1090G>A (p.Ala364Thr), and c.1624G>C (p.Glu542Gln). All 3 variants were located at the last nucleotide of an exon and caused skipping of the exon, leading to frameshifts ( Figure 1E through IG in the Data Supplement). The clinical histories of patients with the c.772G>A variant were significant: 4 had an implantable cardioverter defibrillator in situ, and another had sudden cardiac death ( Table 2) . Three of 4 probands with the c.1624G>C variant had an implantable cardioverter defibrillator in situ, and their maximum septal wall thickness ranged from 25 to 39 mm ( Table 2 ). In contrast, 1 proband and a family member with the c.1624G>C variant had mild hypertrophy.
Variant Classification Using Modified ACMG/AMP Criteria
Functional studies supportive of a damaging effect on the gene product, in a gene where loss of function is an established disease mechanism, is classed as strong evidence of pathogenicity (PS3) by the ACMG/AMP variant classification framework. 4 To evaluate the impact this additional evidence of pathogenicity has on variant classification, we scored the pathogenicity of the 9 MYBPC3 splice-site variants for which we performed RNA functional studies, with and without the outcomes of RNA analysis (Table 3) . Without RNA analysis, 5 variants were classified as pathogenic or likely pathogenic and 4 as variants of uncertain significance. RNA analysis confirmed RNA splicing errors for all 4 variants of uncertain significance and led to a reclassification to likely pathogenic. Two likely pathogenic variants were reclassified to pathogenic, and 1 pathogenic variant remained unchanged with evidence of RNA splicing errors. RNA analysis yielded inconclusive results for 2 likely pathogenic variants, c.927-9G>A and c.3190+5G>A, and, therefore, did not impact on their classifications.
MYBPC3 Splice Variants in ClinVar
We searched the ClinVar database for variants in splicesite regions of MYBPC3 to evaluate the potential untapped pool of variants of uncertain significance that may be reclassified to likely pathogenic after RNA assays. There were 180 unique variants in splice-site regions of MYBPC3, of which 56 (32%) were variants of uncertain significance, 98 (54%) were pathogenic or likely pathogenic, and 26 (14%) were benign or likely benign (Table III in or absent from the gnomAD general population database and have a MaxEntScan predicted impact on splicing (ACMG/AMP criteria PM2 and PP3). This suggests that the addition of functional RNA splicing assays (PS3) may provide sufficient additional support of pathogenicity for reclassification to likely pathogenic.
DISCUSSION
We found rare MYBPC3 splice-site variants in 10% of unrelated probands with HCM. The effects on splicing of 9 variants flanking essential AG and GT splicesite dinucleotides were studied with analysis of RNA extracted from the patient's blood or fixed myocardial tissue. We confirmed that 7 of 9 variants with in silico-predicted effects on splicing caused either exon skipping leading to a frameshift or an in-frame exon truncation. The addition of RNA functional studies led to a reclassification in 6 of 9 MYBPC3 splice-site variants. Of most clinical value, 4 variants in 4 families were reclassified from a variant of uncertain significance to likely pathogenic, enabling this reclassified gene result to be used clinically for cascade genetic testing in the family. Our results highlight the key value of RNA studies for accurate variant annotation and pathogenicity classification using ACMG/AMP guidelines. Many MYBPC3 splice-site variants currently classified as variants of uncertain significance may be upgraded to likely pathogenic following supportive functional studies, leading to a substantial increase in the genetic testing yield of HCM.
RNA sequence analysis can directly confirm the outcomes of RNA splicing. We found that 3 variants annotated as causing a missense change, in fact caused exon skipping and lead to frameshifts. MYBPC3 splice-site variants may cause other unexpected outcomes, such as splicing from alternative sites, as demonstrated with the c.654+5G>C variant and intron retention. 9, 12, 13 Although in silico tools predict whether variants alter RNA splicing, they have low specificity, do not reveal the outcomes of splicing errors, and are not predictive enough to determine the pathogenicity of variants alone.
14 For these reasons, the ACMG/AMP variant classification guidelines class in silico predicted RNA splicing errors as supportive evidence of pathogenicity (PP3) and direct confirmation of a splicing error with functional analysis of RNA as strong evidence (PS3). 15 A key benefit of genetic testing in HCM is to release from life-long clinical surveillance those family members who do not harbor a causal variant. 16 Because variants of uncertain significance are not clinically informative, they are not used for cascade genetic testing of family members. Therefore, reclassification of a variant of uncertain significance to likely pathogenic has the highest clinical value because it allows the family to benefit from a clinically actionable genetic test. ClinVar currently lists 56 variants of uncertain significance in MYBPC3 splice sites for which RNA splicing assays have not been reported. We also recently showed that 9% of HCM patients without a pathogenic variant found following gene panel or exome sequencing are in fact explained by deep intronic variants in MYPBPC3 that cause RNA splicing errors. 17 Collectively, our recent work, and that of others, 18 suggests that analysis of MYBPC3 RNA may be more fruitful in resolving unexplained genetic causes of HCM than searching for the hitherto elusive novel HCM disease genes.
We found people with the same c.1624G>C or c.1624+4A>T variant had marked differences in clinical presentation, ranging from mild HCM to those with severe hypertrophy or sudden cardiac death. It is spec- ulative as to whether MYBPC3 variants that cause RNA splicing errors could contribute to the variable clinical phenotype of HCM. Splice-site variants have rarely been shown to produce exon skipping plus a small proportion of full-length transcripts because of leaky splicing. In 2 consanguineous families with Jervell and LangeNielsen syndrome, patients with a homozygous KCNQ1 c.477+1G>A variant showed 10% of KCNQ1 transcripts without exon skipping. 19 Similarly, a small level of fulllength RARS2 transcripts was amplified from fibroblasts in a family with multiple mitochondrial respiratory chain defects because of a homozygous RARS2 IVS2+5A>G variant. 20 More likely, the incomplete penetrance and clinical variability of HCM are explained by allelic heterogeneity, background genomic variation, and lifestyle factors.
Our study highlighting the key value of RNA splicing assays raises the questions of which sources of RNA are suitable for splicing assays, which technical methods are the most reliable, and who should perform RNA analyses? Although primary cardiac tissue is the most biologically relevant source of RNA, it is largely inaccessible. RNA extracted from fresh venous blood is readily available, supports amplification of MYBPC3 transcripts, and replicates the RNA splicing errors found in myocardial tissue. In the current study, we show that RNA extracted from archival fixed myocardial tissue can facilitate meaningful analysis of splice-site variants. This exciting result suggests that fixed postmortem tissue may also be a source of RNA for the genetic investigation of sudden cardiac death, that is, the molecular autopsy. 21 A limitation of using RNA extracted from fixed tissue is that, because of degradation of the RNA, amplification products should be ≤200 bp.
We were unable to confirm RNA splicing errors because of a c.927-9G>A and c.3190+5G>A variant when using RNA extracted from fresh blood. However, if splice-site variants indeed cause variable levels of RNA splicing errors and disease severity, as discussed above, analysis of the most severely affected family member may increase the chance of finding an RNA splicing error. When patient tissue is not available, in vitro expression of recombinant minigene constructs may be useful, with the limitation that canonical exons are not always recognized and results may be inconsistent with direct analysis of the patient's tissue. A c.927-9G>A variant amplified a faint product smaller than expected, which we were *Functional assay performed in the current study; ACMG/AMP criteria: PS3, supportive functional studies; PS4, variant found in ≥15 probands; PS4_sup, variant found in ≥2 probands; PM2, variant is absent/rare in large population databases; PM4, in-frame protein length change; PP1_str, variant shows ≥7 meioses; PP1_ med, variant shows ≥5 meiosis; PP3, in silico support of pathogenicity.
unable to extract and sequence. Previous analysis of this variant in a minigene assay showed skipping of exon 12, 10 whereas RNA extracted from myocardial tissue of a patient with this variant showed inclusion of intron 11; however, a polymerase chain reaction primer annealing within exon 12 was used, so a product in which exon 12 was skipped would not be detected. 9 Typically, RNA splicing assays are performed as research studies to further elucidate the underlying causes of disease. However, clinically accredited commercial genetic testing centers may also assay splicesite variants if a source of RNA is available. RNA studies involve reverse transcription followed by polymerase chain reaction amplification, which is not overly more complex than Sanger sequencing. Given the benefits of RNA studies for accurate classification of variant pathogenicity, such data is of high clinical value, and the outcomes of RNA analyses should be shared in the public domain for the benefit of others. This is particularly relevant for MYBPC3 splice disrupting variants that are observed in multiple unrelated HCM probands.
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Limitations
The contribution of variants that alter splicing may be greater than we have reported because we did not investigate variants at branch point sequences, or within deep intronic regions, as the targeted sequencing approach of the current study did not cover these regions. We also did not assess coding region variants outside of splicesite regions that may impact on splicing. 18 The majority of our RNA analysis was performed on RNA extracted from venous blood, rather than cardiac tissue. However, there is only 1 main protein-coding transcript of MYB-PC3, and we found consistent results with RNA extracted from blood and cardiac tissue when both were available. Gel electrophoresis-based analysis of reverse transcription polymerase chain reaction products may not have sufficient sensitivity to detect low levels of exon skipping and may require more sensitive assays, such as deep RNA sequencing approaches. Finally, extending our analyses to additional cardiac specific genes may be challenging for genes with low expression levels in blood.
Conclusions
In this study, we demonstrate that RNA-based analysis of MYBPC3 splice-site variants led to 4 variants of uncertain significance being reclassified as likely pathogenic, which enabled cascade testing of the family and improved genetic testing for HCM. We also demonstrate that RNA extracted from fixed myocardial tissue supported meaningful analysis of RNA splicing outcomes and may facilitate the genetic investigation of other inherited heart diseases, including sudden unexplained death. Our results suggest that RNA-based analysis of established HCM disease genes may find more causal variants than a search for novel HCM disease genes. RNA-based analysis of HCM will translate to more accurate diagnosis and management of the disease. 
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